The most feared serious long-term harms — medullary/thyroid C-cell cancer, pancreatic cancer, and other obesity-related cancers — have not shown statistically significant elevation in pooled randomized and cohort data to date, though absolute event counts are small and dedicated cancer-outcome studies beyond ~2-4 years are still lacking.

Evidence (1)

Assessing the oncological safety of GLP-1 receptor agonists: systematic review and meta-analysis

No statistically significant increase in thyroid, pancreatic, or obesity-related cancer risk in pooled data; authors note longer cancer-focused follow-up is still needed.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12676983/

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/59022fce832d58171d6cbb05b2f87ed302610d56af11a472c83aee638143e1a0"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.